Iovance Biotherapeutics
Iovance Biotherapeutics is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lympocyte (TIL) therapies against cancer.[1][2]
 | |
| Public | |
| Traded as | NASDAQ: IOVA |
| Industry | Biotechnology, Pharmaceutical, Cancer immunotherapy |
| Founded | 2007 |
| Headquarters | , United States of America |
Key people | Steven Rosenberg |
| Website | www |
History
The company was founded in 2007 as Lion Biotechnologies. In 2013, Lion merged with Genesis Biopharma, and rebranded to Iovance in 2017.[3]
Drug pipeline
Iovance has a TIL treatment undergoing clinical trials against melanoma (investigational id: LN-144, tradename: Lifileucel). In partnership with MedImmune, Iovance is investigating a TIL therapy against cervical and head and neck cancers (investigational id: LN-145).
See also
References
- Garber, Ken (7 August 2019). "Pursuit of tumor-infiltrating lymphocyte immunotherapy speeds up". Nature Biotechnology. Retrieved 14 August 2019.
- Adelman, Jacob (29 May 2019). "New Navy Yard lab and office complex planned for Calif. cell-therapy research firm Iovance". The Philadelphia Inquirer. Retrieved 14 August 2019.
- "Genesis Biopharma Announces Completion of Merger with Lion Biotechnologies". www.businesswire.com. 2013-07-25. Retrieved 2020-01-17.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.